Drug safety assessment in clinical trials: methodological challenges and opportunities
<p>Abstract</p> <p>Randomized controlled trials are the principal means of establishing the efficacy of drugs. However pre-marketing trials are limited in size and duration and exclude high-risk populations. They have limited statistical power to detect rare but potentially serious...
Main Authors: | Singh Sonal, Loke Yoon K |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-08-01
|
Series: | Trials |
Online Access: | http://www.trialsjournal.com/content/13/1/138 |
Similar Items
-
Big Data in Designing Clinical Trials: Opportunities and Challenges
by: Charles S. Mayo, et al.
Published: (2017-08-01) -
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
by: Aronson Jeffrey K, et al.
Published: (2001-09-01) -
Drug-drug cocrystals: Opportunities and challenges
by: Xiaojuan Wang, et al.
Published: (2021-05-01) -
Opportunities and challenges in oncology targeted drug development : an assessment of the use of prevalence and companion diagnostic performance thresholds to guide clinical trial strategies
by: Vital, Heather Stacey Tomkinson
Published: (2013) -
Digital Twins in Healthcare: Methodological Challenges and Opportunities
by: Charles Meijer, et al.
Published: (2023-10-01)